Intelligence Feed event · Equity · 2026-10-04

    DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1

    Question

    DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1

    Direct answer

    Dialysis provider DaVita is heading into its third-quarter earnings release with consensus expectations pointing to $3.78 per share, reflecting a 50.6% increase over the prior year. The performance follows operational efficiencies across outpatient treatment centers. The equity trades at a forward price-to-earnings ratio of 12.1, representing a substantial discount to the broader medical services peer multiple of 19.68. Pricing realization per treatment and patient volume metrics will determine post-earnings valuation revisions.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1”, revision 1, evidence through 2026-10-04. https://marketontology.com/market-events/2026-10-04/davita-projects-q3-eps-growth-of-50-6-yoy-to-3-78-with-forward-p-e-at-12-1-093b3b

    EQUITY
    DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1
    Dialysis provider DaVita is heading into its third-quarter earnings release with consensus expectations pointing to $3.78 per share, reflecting a 50.6% increase over the prior year. The performance follows operational efficiencies across outpatient treatment centers. The equity trades at a forward price-to-earnings ratio of 12.1, representing a substantial discount to the broader medical services peer multiple of 19.68. Pricing realization per treatment and patient volume metrics will determine post-earnings valuation revisions.
    DVA
    Impact
    69
    OCT 4
    SIG
    86%
    DVA
    DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1
    Dialysis provider DaVita is heading into its third-quarter earnings release with consensus expectations pointing to $3.78 per share, reflecting a 50.6% increase over the prior year. The performance follows operational efficiencies across outpatient treatment centers. The equity trades at a forward price-to-earnings ratio of 12.1, representing a substantial discount to the broader medical services peer multiple of 19.68. Pricing realization per treatment and patient volume metrics will determine post-earnings valuation revisions.
    → Outsized EPS expansion against a discounted 12.1 forward P/E multiple drives multiple rerating at DVA toward the healthcare industry benchmark.
    Impact
    Dialysis provider DaVita is heading into its third-quarter earnings release with consensus expectations pointing to $3.78 per share, reflecting a 50.6% increase over the prior year. The performance follows operational efficiencies across outpatient treatment centers. The equity trades at a forward price-to-earnings ratio of 12.1, representing a substantial discount to the broader medical services peer multiple of 19.68. Pricing realization per treatment and patient volume metrics will determine post-earnings valuation revisions.
    Affected
    DVA
    Transmission
    Outsized EPS expansion against a discounted 12.1 forward P/E multiple drives multiple rerating at DVA toward the healthcare industry benchmark.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    DVAearnings per share growth flowing into forward price-to-earnings multiple expansionUp1-4wProjected Q3 earnings of $3.78 per share represents 50.6% YoY growth at 12.1 forward P/E.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month